DGDaniel Galdo-Torres

Daniel Galdo-Torres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Galdo-Torres has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From HSV-2 to HSV-1: A change in the epidemiology of genital herpes

    by Sabina Andreu, Daniel Galdo-Torres, Inés Ripa, Oliver Caballero, Raquel Bello-Morales, José Antonio López-Guerrero


  • Open Access

    Discovery of a Baloxavir‐Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo

    by Sabina Andreu, Kai Tang, Jiahui Zhou, Gabriel Pino‐Peco, Nerea López‐Carrobles, Raquel Bello‐Morales, Daniel Galdo‐Torres, Lina Zhang, Federico Gago, José Antonio López‐Guerrero, et al.

    Herpes simplex viruses (HSV‐1 and HSV‐2) are highly prevalent and contagious, causing lifelong infections that cannot be eradicated with current therapies. Acyclovir and other viral DNA polymerase inhibitors are effective antiviral agents for treating HSV infections. However, despite the recent approval of pritelivir and amenamevir (helicase–primase complex inhibitors), drug resistance is still a major threat to therapeutic success. This research focuses on developing new antiviral strategies against HSV‐1 by targeting the pUL15 endonuclease, a component of the viral packaging motor/terminase complex, using substituted polycyclic pyridones derived from baloxavir acid. Several compounds display low micromolar IC 50 values in enzymatic assays. Among them, the prioritized compound, LN‐7 , shows a 50% effective concentration (EC 50 ) of 2.8 ± 1.1 µ m in antiviral assays and favorable pharmacokinetic properties in rats. LN‐7 demonstrates antiviral efficacy in infected mice, while exhibiting fewer clinical signs compared to controls. Overall, LN‐7 emerges as a promising lead for treating herpesvirus infections and is therefore a first‐in‐class drug candidate targeting HSV genome packaging.


  • Open Access

    Polyclonal LC3B Antibodies Generate Non-Specific Staining in the Nucleus of Herpes Simplex Virus Type 1-Infected Cells: Caution in the Interpretation of LC3 Staining in the Immunofluorescence Analysis of Viral Infections

    by Inés Ripa, Sabina Andreu, Daniel Galdo, Oliver Caballero, Raquel Bello-Morales, José Antonio López-Guerrero

    The most common marker used to monitor autophagy is the microtubule-associated protein light chain 3 (LC3). Upon induction of autophagy, LC3 is conjugated to phosphatidylethanolamine and targeted to autophagic membranes, which can be easily detected by immunofluorescence. However, this technique has some limitations. During the early stages of HSV-1 infection, strong LC3B nuclear staining is observed within the viral replication compartments. This staining is only detected when using polyclonal antibodies. It is noteworthy that monoclonal antibodies or the GFP-LC3 plasmid do not reveal any nuclear LC3 staining. Interestingly, LC3B is not detected in the nuclear fraction of infected cells by Western blotting, even when polyclonal antibodies are used. In infected LC3B knockout cells, nuclear staining is still observed when using polyclonal LC3B antibodies. This suggests that polyclonal LC3B antibodies generate non-specific nuclear staining in infected cells, which could result in misinterpretation and erroneous conclusions. These findings raise questions about the reliability of LC3-immunofluorescence assays in herpesvirus infections. It is imperative that the methodology employed for monitoring autophagy by immunofluorescence in viral infections be reviewed and updated, and that the specificity of anti-LC3B antibodies be tested before use. To ensure the accuracy of the results, it is essential to validate this technique with additional assays, such as by immunoblot analysis or via the use of autophagy-deficient cell lines.

  • Open Access

    Immune Modulatory Effects of Vitamin D on Herpesvirus Infections

    by Daniel Galdo-Torres, Sabina Andreu, Oliver Caballero, Israel Hernández-Ruiz, Inés Ripa, Raquel Bello-Morales, José Antonio López-Guerrero

    In addition to its classical role in calcium and phosphate metabolism regulation, vitamin D also has an important impact on immunity modulation. Vitamin D regulates the immune response, shifting from a proinflammatory state to a more tolerogenic one by increasing the release of anti-inflammatory cytokines while downregulating proinflammatory cytokines. Thus, low levels of vitamin D have been associated with an increased risk of developing autoimmune diseases like multiple sclerosis and type 1 diabetes. Furthermore, this prohormone also enhances the release of well-known antimicrobial peptides, like cathelicidin LL-37 and β-defensins; therefore, it has been proposed that vitamin D serum levels might be related to the risk of well-known pathogen infections, including herpesviruses. These are a group of widely spread viral pathogens that can cause severe encephalitis or tumors like Kaposi’s sarcoma and Burkitt lymphoma. However, there is no consensus on the minimum levels of vitamin D or the recommended daily dose, making it difficult to establish a possible association between these two factors. This narrative non-systematic review will analyze the mechanisms by which vitamin D regulates the immune system and recent studies about whether there is an association between vitamin D serum levels and herpesvirus infections.